Xi huang pills enhance the tumor treatment efficacy when combined with chemotherapy: A meta-analysis and systematic review.
To evaluate Xi huang pill combined with chemotherapy for tumor treatment in a meta-analysis. We searched PubMed, Excerpta Medica Database, the Cochrane Library, the China National Knowledge Infrastructure, and the Weipu database and Wanfang Databases for eligible studies. We manually searched for printed journals and relevant textbooks. Statistical analyses were performed with Review Manager 5.3 (Cochrane Community, London, United Kingdom) and STATA 12.0 software packages. Fifteen studies were included. Xi huang pill combined with chemotherapy could enhance response (risk ratio [RR] =1.35, 95% confidence interval [95% CI]: 1.14-1.60, P < 0.0004), improve disease control (RR = 1.13, 95% CI: 1.05-1.21, P = 0.0006), prolong overall survival (hazard ratio = 0.80, 95% CI: 0.08-0.98, P = 0.03), improve patient quality of life (RR = 1.35, 95% CI: 1.10-1.67, P < 0.004), reduce 2-4° leukocyte (white blood cell) and platelet count due to chemotherapy (pooled RR = 0.42, 95% CI = 0.30-0.60, pooled RR = 0.42, 95% CI = 0.25-0.72, respectively). Xi huang pill combined with chemotherapy can enhance the short-term efficacy and overall survival, alleviate treatment-induced side effects, and serve as a suitable regimen for the treatment of patients with tumors. However, the findings of the current study require validation in further high-quality trials.